Nitric oxide: Protein tyrosine phosphorylation and protein S-nitrosylation in cancer

Cancer is a worldwide health problem leading to a high incidence of morbidity and mortality. Malignant transformation can occur by expression of oncogenes, over-expression and deregulated activation of proto-oncogenes, and inactivation of tumor suppressor genes. These cellular actions occur through stimulation of oncogenic signaling pathways. Nitric oxide (NO) can induce genetic changes in cells and its intracellular generation can lead to tumor formation and progression. It can also promote anti-tumor activities. The pro- and anti-tumor activities of NO are dependent on its intracellular concentration, cell compartmentalization, and cell sensitivity. NO affects a number of oncogenic signaling pathways. This review focuses on two oncogenic signaling pathways: NO-EGFR-Src-FAK and NO-Ras-EGFR-ERK1/2 MAP kinases. In these pathways, low to intermediate concentrations of NO/S-nitrosothiols (RSNOs) stimulate oncogenic signaling, while high concentrations of NO/RSNO stimulate anti-oncogenic signaling. Increasing knowledge on pro- and anti-tumorigenic activities of NO and related reactive species such as RSNOs has fostered the research and synthesis of novel NO-based chemotherapeutic agents. RSNOs, effective as NO donors and trans-nitrosylating agents under appropriate conditions, may operate as potential chemotherapeutic agents.

[1]  J. Stamler,et al.  The SNO-proteome: causation and classifications. , 2011, Current opinion in chemical biology.

[2]  S. Ambs,et al.  Molecular mechanisms for discrete nitric oxide levels in cancer. , 2008, Nitric oxide : biology and chemistry.

[3]  E. Masini,et al.  Relaxin activates the L-arginine-nitric oxide pathway in human breast cancer cells. , 1995, Cancer research.

[4]  L. Magnelli,et al.  Inducible nitric oxide synthase activity correlates with lymphangiogenesis and vascular endothelial growth factor‐C expression in head and neck squamous cell carcinoma , 2006, The Journal of pathology.

[5]  C. R. Oliveira,et al.  The low molecular weight S-nitrosothiol, S-nitroso-N-acetylpenicillamine, promotes cell cycle progression in rabbit aortic endothelial cells. , 2008, Nitric oxide : biology and chemistry.

[6]  P. Lirk,et al.  Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. , 2005, Seminars in cancer biology.

[7]  H. Masutani,et al.  Thioredoxin-1 promotes survival in cells exposed to S-nitrosoglutathione: Correlation with reduction of intracellular levels of nitrosothiols and up-regulation of the ERK1/2 MAP Kinases. , 2008, Toxicology and applied pharmacology.

[8]  R. Arai,et al.  The nitric oxide-sensitive p21Ras-ERK pathway mediates S-nitrosoglutathione-induced apoptosis. , 2008, Biochemical and biophysical research communications.

[9]  J S Beckman,et al.  Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.

[10]  D. Townsend,et al.  The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer. , 2011, Free radical biology & medicine.

[11]  T. Senga,et al.  S-Nitrosylation at Cysteine 498 of c-Src Tyrosine Kinase Regulates Nitric Oxide-mediated Cell Invasion* , 2009, The Journal of Biological Chemistry.

[12]  D. Wink,et al.  Biological Nitric Oxide Signaling : Chemistry and Terminology ( NO Chemical Biology and Terminology ) , 2013 .

[13]  H. E. Marshall,et al.  Protein S-nitrosylation: purview and parameters , 2005, Nature Reviews Molecular Cell Biology.

[14]  C. Cross,et al.  Formation of Reactive Nitrogen Species during Peroxidase-catalyzed Oxidation of Nitrite , 1997, The Journal of Biological Chemistry.

[15]  M. Loda,et al.  Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. , 2009, The Journal of clinical investigation.

[16]  L. Liaudet,et al.  Nitric oxide and peroxynitrite in health and disease. , 2007, Physiological reviews.

[17]  S. Ménard,et al.  Expression of protein tyrosine phosphatase alpha (RPTPα) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo , 2000, Oncogene.

[18]  C. Graham,et al.  Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. , 2009, Urology.

[19]  L. C. de Oliveira,et al.  Nitric oxide stimulates tyrosine phosphorylation of focal adhesion kinase, Src kinase, and mitogen-activated protein kinases in murine fibroblasts. , 2000, Free radical biology & medicine.

[20]  S. Ambs,et al.  S-Nitrosylation of EGFR and Src Activates an Oncogenic Signaling Network in Human Basal-Like Breast Cancer , 2012, Molecular Cancer Research.

[21]  Rafael Germano Santana,et al.  1H and 13C NMR analysis of 2‐acetamido‐3‐mercapto‐3‐methyl‐N‐aryl‐butanamides and 2‐acetamido‐3‐methyl‐3‐nitrososulfanyl‐N‐aryl‐butanamide derivatives , 2013, Magnetic resonance in chemistry : MRC.

[22]  S. Gross,et al.  Balancing reactivity against selectivity: the evolution of protein S-nitrosylation as an effector of cell signaling by nitric oxide. , 2007, Cardiovascular research.

[23]  H. Kruszyna,et al.  Bioactivation of nitroprusside by porcine endothelial cells. , 1994, Toxicology and applied pharmacology.

[24]  R. Arai,et al.  S-nitrosoglutathione and endothelial nitric oxide synthase-derived nitric oxide regulate compartmentalized ras S-nitrosylation and stimulate cell proliferation. , 2013, Antioxidants & redox signaling.

[25]  D. Bar-Sagi,et al.  Regulating the regulator: post-translational modification of RAS , 2011, Nature Reviews Molecular Cell Biology.

[26]  V. Gladyshev,et al.  Structural analysis of cysteine S-nitrosylation: a modified acid-based motif and the emerging role of trans-nitrosylation. , 2010, Journal of molecular biology.

[27]  T. Poulos,et al.  Targeting nitric oxide signaling with nNOS inhibitors as a novel strategy for the therapy and prevention of human melanoma. , 2013, Antioxidants & redox signaling.

[28]  Xinyang Zheng,et al.  Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase , 1992, Nature.

[29]  C. Nathan,et al.  Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells , 1989, The Journal of experimental medicine.

[30]  H. Masutani,et al.  Deficiency of Thioredoxin Binding Protein-2 (TBP-2) Enhances TGF-β Signaling and Promotes Epithelial to Mesenchymal Transition , 2012, PloS one.

[31]  H. Masutani,et al.  Nitrosative/Oxidative Stress Conditions Regulate Thioredoxin-Interacting Protein (TXNIP) Expression and Thioredoxin-1 (TRX-1) Nuclear Localization , 2013, PloS one.

[32]  C. Marshall,et al.  All ras proteins are polyisoprenylated but only some are palmitoylated , 1989, Cell.

[33]  R. Arai,et al.  Protein tyrosine phosphorylation and protein tyrosine nitration in redox signaling. , 2008, Antioxidants & redox signaling.

[34]  D. Hirst,et al.  The contribution of N2O3 to the cytotoxicity of the nitric oxide donor DETA/NO: an emerging role for S-nitrosylation , 2013, Bioscience reports.

[35]  S. Campbell,et al.  Mechanism of p21Ras S-nitrosylation and kinetics of nitric oxide-mediated guanine nucleotide exchange. , 2004, Biochemistry.

[36]  C. Croce.  Oncogenes and cancer. , 2008, The New England journal of medicine.

[37]  K. Lim,et al.  Tumour maintenance is mediated by eNOS , 2008, Nature.

[38]  H. Monteiro.  Signal transduction by protein tyrosine nitration: competition or cooperation with tyrosine phosphorylation-dependent signaling events? , 2002, Free radical biology & medicine.

[39]  B. Rigas.  Novel agents for cancer prevention based on nitric oxide. , 2007, Biochemical Society transactions.

[40]  R. Jain,et al.  The role of nitric oxide in tumour progression , 2006, Nature Reviews Cancer.

[41]  C. Graham,et al.  Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells , 2006, Breast Cancer Research and Treatment.

[42]  A. Reznick,et al.  The expression of iNOS and nitrotyrosine in colitis and colon cancer in humans. , 2012, Acta histochemica.

[43]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  A. Stern,et al.  Nitric oxide stimulates tyrosine phosphorylation in murine fibroblasts in the absence and presence of epidermal growth factor. , 1995, The Biochemical journal.

[45]  M. Curcio,et al.  Protein tyrosine phosphatase alpha regulates cell detachment and cell death profiles induced by nitric oxide donors in the A431 human carcinoma cell line , 2011, Redox report : communications in free radical research.

[46]  A. Stern,et al.  A Role for Nitric Oxide and for Nitric Oxide Synthases in Tumor Biology , 2012 .

[47]  Y. Rojanasakul,et al.  Nitrosothiol signaling and protein nitrosation in cell death. , 2014, Nitric oxide : biology and chemistry.

[48]  J. Pouysségur,et al.  Cyclin D1 Expression Is Regulated Positively by the p42/p44MAPK and Negatively by the p38/HOGMAPK Pathway* , 1996, The Journal of Biological Chemistry.

[49]  J. Gratton,et al.  S-nitrosylation of beta-catenin by eNOS-derived NO promotes VEGF-induced endothelial cell permeability. , 2010, Molecular cell.

[50]  L. Moroz,et al.  On the comparative biology of Nitric Oxide (NO) synthetic pathways: Parallel evolution of NO-mediated signaling , 2007 .

[51]  H. Tinsley,et al.  cGMP signaling as a target for the prevention and treatment of breast cancer. , 2015, Seminars in cancer biology.

[52]  F. Murad,et al.  Role of cyclic‐GMP in Relaxations of Vascular mooth Muscle , 1985, Journal of cardiovascular pharmacology.

[53]  Eleftherios P. Diamandis,et al.  Novel therapeutic applications of cardiac glycosides , 2008, Nature Reviews Drug Discovery.

[54]  E. Grimm,et al.  Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. , 2008, Nitric oxide : biology and chemistry.

[55]  M. Curcio,et al.  Endothelium-derived nitric oxide (NO) activates the NO-epidermal growth factor receptor-mediated signaling pathway in bradykinin-stimulated angiogenesis. , 2014, Archives of biochemistry and biophysics.

[56]  S. F. Pearce,et al.  Nitric Oxide-stimulated Guanine Nucleotide Exchange on p21ras(*) , 1995, The Journal of Biological Chemistry.

[57]  R. Weinberg,et al.  The Biology of Cancer , 2006 .

[58]  A. Zeiher,et al.  Nitric oxide and apoptosis: another paradigm for the double-edged role of nitric oxide. , 1997, Nitric oxide : biology and chemistry.

[59]  R. Arai,et al.  Nitric oxide and cGMP activate the Ras-MAP kinase pathway-stimulating protein tyrosine phosphorylation in rabbit aortic endothelial cells. , 2003, Free radical biology & medicine.

[60]  S. Padmaja,et al.  The reaction of no with superoxide. , 1993, Free radical research communications.

[61]  P. Casey,et al.  p21ras is modified by a farnesyl isoprenoid. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Eric J. Toone,et al.  (S)NO Signals: Translocation, Regulation, and a Consensus Motif , 1997, Neuron.

[63]  K. Yeung,et al.  Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases. , 2008, Nitric oxide : biology and chemistry.

[64]  A. Ambrósio,et al.  Nitric oxide from inflammatory origin impairs neural stem cell proliferation by inhibiting epidermal growth factor receptor signaling , 2014, Front. Cell. Neurosci..

[65]  R. Zhao,et al.  Thioredoxin 1 as a subcellular biomarker of redox imbalance in human prostate cancer progression. , 2010, Free radical biology & medicine.

[66]  Ming Xian,et al.  Nitric oxide donors: chemical activities and biological applications. , 2002, Chemical reviews.

[67]  S. Cadenas,et al.  Nitric oxide signaling: classical, less classical, and nonclassical mechanisms. , 2011, Free radical biology & medicine.

[68]  Martin Feelisch,et al.  Methods in nitric oxide research , 1996 .

[69]  S. Snyder,et al.  Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis , 2008, Nature Cell Biology.

[70]  S. Moncada,et al.  An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[71]  M. Curcio,et al.  Regulatory effects of nitric oxide on Src kinase, FAK, p130Cas, and receptor protein tyrosine phosphatase alpha (PTP-alpha): a role for the cellular redox environment. , 2010, Antioxidants & redox signaling.

[72]  H. Masutani,et al.  Nitric oxide induces thioredoxin-1 nuclear translocation: possible association with the p21Ras survival pathway. , 2006, Biochemical and biophysical research communications.

[73]  J. Peacock,et al.  Protein-tyrosine Phosphatase α Regulates Src Family Kinases and Alters Cell-Substratum Adhesion* , 1998, The Journal of Biological Chemistry.

[74]  J. Pouysségur,et al.  The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition , 2007, Oncogene.

[75]  N. Holbrook,et al.  Cellular response to oxidative stress: Signaling for suicide and survival * , 2002, Journal of cellular physiology.

[76]  B. Bonavida,et al.  Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer. , 2013, Nitric oxide : biology and chemistry.

[77]  C. Counter,et al.  Decreased tumorigenesis in mice with a Kras point mutation at C118 , 2014, Nature Communications.

[78]  C. Albanese,et al.  Transforming p21ras Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions (*) , 1995, The Journal of Biological Chemistry.

[79]  B. Peng,et al.  Overexpression of thioredoxin system proteins predicts poor prognosis in patients with squamous cell carcinoma of the tongue. , 2011, Oral oncology.

[80]  S. Cadenas,et al.  Corrigendum to “Nitric oxide signaling: Classical, less classical, and nonclassical mechanisms” [Free Radic. Biol. Med. 51 (2011) 17–29] , 2011 .

[81]  A. Stern,et al.  Nitric oxide: a potential inducer of adhesion-related apoptosis--anoikis. , 2004, Nitric oxide : biology and chemistry.

[82]  D. Schlaepfer,et al.  Integrin-regulated FAK-Src signaling in normal and cancer cells. , 2006, Current opinion in cell biology.

[83]  O. Augusto,et al.  Connecting the chemical and biological properties of nitric oxide. , 2012, Chemical research in toxicology.

[84]  H. P. Monteiro,et al.  Arginase 2 and nitric oxide synthase: Pathways associated with the pathogenesis of thyroid tumors. , 2010, Free radical biology & medicine.